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Background: Periostin, a matricellular protein, has been reported to play a 
crucial role in fibrosis. Acute kidney injury results in a high risk of 
progression to chronic kidney disease. It was hypothesized that periostin is 
involved in the progression of acute kidney injury to kidney fibrosis. 
Methods: Unilateral ischemia-reperfusion injury using 7- to 8-week-old male 
wild-type and periostin null mice was induced and the animals were 
observed for 6 weeks. In vitro, human kidney-2 cells were subjected to a 
hypoxic incubator (5% O2, 5% CO2, and 90% N2) for 24 hours and 5 days. 
The cells were also cultured with a p38 mitogen-activated protein kinase 
(MAPK) inhibitor in the hypoxic incubator for 5 days.
Results: At 6 weeks after induction of unilateral ischemia-reperfusion injury, 
the kidneys in periostin null mice were less atrophied, and interstitial 
fibrosis/tubular atrophy was significantly alleviated in periostin null mice 
compared with those in wild-type mice. The expressions of 
phosphorylated-p38 MAPK were also decreased in periostin null mice 
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compared to those in wild-type mice. Furthermore, periostin null mice had 
attenuated mRNA and protein expression of fibrosis and apoptosis markers. 
In vitro, hypoxic injury (5% O2, 5% CO2, and 90% N2) of the human 
kidney-2 cells for 24 hours and 5 days increased the expressions of 
phosphorylated-p38 MAPK and fibrosis markers. Recombinant periostin in 
hypoxic conditions enhanced phosphorylated-p38 MAPK expression, which 
was comparable to that with recombinant transforming growth factor-β1. In 
contrast, inhibition of p38 MAPK ameliorated hypoxia-induced fibrosis. 
Conclusion: In conclusion, periostin promotes kidney fibrosis via the p38 
MAPK pathway following acute kidney injury triggered by hypoxic or 
ischemic insult. Periostin ablation could protect against kidney progression.
----------------------------------------------------------------------------------------------------
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Introduction
  Periostin, a matricellular protein, is associated with normal development of 
teeth, bone, heart, and kidney during the embryonic period [1-3], but 
thereafter, its expression has been associated with congestive heart failure [4, 
5], myocardial infarction [6, 7], muscle injury, asthma [8], and development 
and metastasis of various malignancies [9-11]. In addition, previous clinical 
and experimental studies have reported that periostin was highly expressed in 
fibrotic tissues [12, 13] and associated with disease severity in several 
chronic kidney disease (CKD) models such as diabetic nephropathy or 
hypertensive nephropathy [14].
  Periostin primarily binds to integrin, and crosstalk with receptor tyrosine 
kinases, such as epidermal growth factor receptor in the plasma membrane, 
is observed. Then, it activates the AKT- or FAK-mediated signaling pathway 
and regulates various cell functions, including cell adhesion, mobility, 
migration, survival, proliferation, and angiogenesis [15]. Moreover, is binds 
extracellular matrix molecules, such as collagen IV and fibronectin, which 
leads to extracellular matrix remodeling, organization, fibrillogenesis, and 
epithelial-mesenchymal transition [16-18].
  Acute kidney injury (AKI) occurs in 5-10% of hospitalized patients and 
in more than 30% of critically ill patients [19]. The incidence of AKI has 
increased every year [19], which has major direct and indirect clinical 
implications. AKI results in impeded treatment for comorbidities, increased 
risk of acute renal replacement therapy, longer hospital stays, increased 
burden of medical costs, and increased mortality rates (up to 50-80%) [20, 
21].
  Furthermore, AKI patients showed a higher risk of progression to CKD 
[22], which was substantial when the AKI patients experienced more 
episodes and more severe injury [23, 24]. Recently, it was reported that 
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severe AKI patients requiring continuous renal replacement therapy (CRRT)
had a greater risk of progression to end-stage renal disease compared to that 
of stage 3 CKD patients who did not undergo an AKI episode, even if 
their renal function recovered at 3 months [25].
  Similarly, periostin plays a crucial role in the fibrosis in diverse organs, 
including the kidney; however, the association between the progression of 
AKI to CKD and periostin has not been investigated. In the present study, a 
“progression of AKI to CKD model” was established and the effects of 
periostin were analyzed. Then, whether the inhibition of periostin was a 





Male wild-type (WT) mice (C57BL/6; B6) were purchased from Koatech 
(Seoul, Korea) and male periostin (Postn) null mice (Postn-/-) 
(B6;129-Postntm1Jmol/J) [26] were purchased from the Jackson Laboratory (Bar 
Harbor, ME, USA). All of the 7- to 8-week-old mice used in the 
experiments were raised in a specific pathogen-free animal facility. All 
experiments were performed under the approval of the Institutional Animal 
Care and Use Committee of Clinical Research Institute at Seoul National 
University Boramae Medical Center (2016-0001) and in accordance with the 
Guidelines for the Care and Use of Laboratory Animals of the National 
Research Council and the NIH guide for the Care and Use of Laboratory 
Animals.
Establishment of progressive kidney injury in vivo model
A “progression of AKI to CKD model” was designated as the 
“progressive kidney injury model”. Firstly, to establish a progressive kidney 
injury in vivo model, unilateral ischemia-reperfusion injury (UIRI) was 
induced in the left kidney pedicle for 30 minutes in WT mice and Postn 
null mice. The mice were anesthetized with xylazine (Rompun; 10 mg/kg; 
Bayer, Canada) and tiletamine mixed with zolazepam (1:1) (ZoletilTM; 30 
mg/kg; Virbac, USA). After unilateral flank incision, the left renal pedicle 
was cross-clamped for 30 minutes with microaneurysm clamps (Roboz 
Surgical Instrument Co., Gaithersburg, MD), and then, reperfusion was 
performed. During the procedure, pre-warmed (37°C) PBS (500 µl) was 
administered intraperitoneally for optimal fluid balance, and the animals were 
placed on a heating pad (37°C). Sham-operated mice received the same 
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surgical procedure except for the clamping of renal pedicle. After 6 weeks, 
mice were sacrificed, and blood, urine, and kidney tissues were obtained. 
Gross features and the weights of both kidneys were examined, and the 
weight ratios of left kidney to right kidney were analyzed.
Establishment of progressive kidney injury in vitro model
For the progressive kidney injury in vitro model, a “hypoxia induced 
fibrosis” experiment was performed. The human kidney-2 (HK-2) cell line 
(ATCC® CRL-2190TM, Manassas, Virginia, USA), an immortalized proximal 
tubule epithelial cell line, was used. The cells were incubated in DMEM/F12 
medium and cultured on petri dishes (BD Biosciences, Franklin Lakes, NJ, 
USA) until colonies were established, and passages 2 to 3 were used in this 
study. Then, HK-2 cells (2×105/well) were plated into a 6-well plate. After 
starvation in serum-free media for 24 hours, HK-2 cells were incubated with 
recombinant transforming growth factor-beta1 (rTGF-β1, 2 ng/mL) at 21% 
O2, 5% CO2, and 74% N2, which was used as a positive control. For 
hypoxia induction, HK-2 cells also were subjected to a hypoxic incubator 
(5% O2, 5% CO2, and 90% N2). Under this condition, after 24 hours, the 
expression of phosphorylated p38 mitogen-activated protein kinase 
(phospho-p38 MAPK) was observed as an acute response of hypoxia; then, 
fibrosis was induced via hypoxia injury for 5 days. Moreover, to assess the 
protective effect on fibrosis, the cells were pre-treated for 1 hour and 
cultured with a p38 MAPK inhibitor (SB-731445) [27], supplied by GSK 
Global (Hertfordshire, UK), at concentrations of 1 and 2 µM, in the 
hypoxic incubator for 5 days.
Histological analyses
For histological analyses, 4 µm-thick paraffin sections were stained with 
Masson’s trichrome and Sirius red. For immunohistochemistry assays, 
9
paraffin-embedded kidneys cut into 4 µm-thick slices were deparaffinized 
and hydrated using xylene and ethanol. Endogenous biotin activity was 
blocked by 3% hydrogen peroxide. Deparaffinized sections were stained with 
anti-collagen 1A1 antibody (Abcam, Cambridge, MA, USA), anti-S100A4 
antibody (Abcam), anti-cleaved caspase-3 antibody (Cell Signaling, Danvers, 
MA, USA), or anti-phospho-p38 MAPK antibody (Cell Signaling), and then 
incubated with HRP-conjugated goat anti-rabbit IgG (Vector Laboratories, 
Burlingame, CA, USA). The 3, 3'-diaminobenzidine tetrahydrochloride 
(Sigma-Aldrich, Saint Louis, MO, USA) were used for immunhistochemical 
detection. Finally, all sections were counterstained with Mayer’s hematoxylin 
(Sigma-Aldrich) and evaluated under light microscopy. For each sample, 5 
fields (100× magnification) were assessed for positive staining (%) by a 
morphometry system (Qwin 3, Leica, Netherlands). 
Confocal microscopic examination
To detect the expression of phospho-p38 MAPK, the sections were 
stained with anti-phospho-p38 MAPK antibody (Cell Signaling) in a blocking 
reagent overnight at 4oC. A second layer of Alexa Fluor® 555-conjugated 
goat anti-rabbit antibody (Molecular Probes, Eugene, OR, USA) was applied 
and incubated at room temperature for one hour. All sections were washed 
and then incubated for an additional 5 minutes with 4', 
6-diamidino-2-phenylindole (DAPI, Molecular Probes) for counterstaining. For 
the negative controls, primary antibody was omitted from sections. Sections 
were blindly and randomly evaluated, and images were captured using a 
Leica TCS SP8 STED CW (Leica, Mannheim, Germany) and MetaMorph 
version 7.8.10 software (Universal Imaging, Downingtown, PA). 
For in vitro studies, HK-2 cells cultured with rTGF-β1 (2 ng/mL) or 
recombinant periostin (rPeriostin) (1000 ng/mL; R&D systems, Minneapolis, 
MN, USA) were incubated. After 24 hours, immunofluorescence staining was 
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performed for DAPI and phospho-p38 MAPK. The proportions of 
phospho-p38 MAPK-positive cells were assessed for quantitative analysis.
Quantitative real-time PCR
Total RNA was isolated from mouse kidney tissues 6 weeks after disease 
induction, and the mRNA levels were analyzed by real-time PCR. Briefly, 1 
µg of total RNA extracted using the RNeasy kit (Qiagen GmBH, Hilden, 
Germany) was reverse-transcribed using oligo-d(T) primers and AMV-RT 
Taq polymerase (Promega, Madison, WI, USA). Real-time PCR was 
performed using either an Assay-on-Demend TaqMan probes or the SYBR 
Green method and primers for α-smooth muscle actin (α-SMA), fibronectin, 
collagen 1A1, periostin, TGF-β1, p53, caspase-9, glycogen synthase kinase 
3β (GSK3β), p38 MAPK, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Applied Biosystems, Foster City, CA, USA) with an ABI PRISM 
7500 Sequence Detection System. Relative quantification was done using the 
ΔΔCT method. The mRNA expression levels were normalized using the 
GAPDH mRNA expression. 
Western blot analyses
Kidney tissues were harvested from mice 6 weeks after disease induction, 
and cells were collected 5 days after the establishment of the in vitro
model. After protein extraction from tissues and cells, equal amounts (80 
µg) were separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide 
gels and transferred onto Immobilon-FL 0.4 µM polyvinylidene difluoride 
membranes (Millipore, Bedford, MA, USA). Primary antibodies targeting β
-actin (Sigma-Aldrich), fibroblast-specific protein-1 (FSP-1), α-SMA, 
E-cadherin, fibronectin, B-cell lymphoma 2 (Bcl-2), collagen 1A1, periostin, 
and snail (Abcam) were used. Anti-mouse IgG and anti-rabbit IgG (Vector 
Laboratories) was used as secondary antibodies. The target molecule 
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expression levels were normalized with respect to the amount of β-actin 
expression. Densitometry was performed using the gel analysis process of 
ImageJ software (National Institutes of Health, Bethesda, Maryland, USA). 
After densitometric analyses of various markers in all tissue and cellular 
samples, only representative samples were shown in the figures.
Statistics
The results are expressed as the mean ± standard deviation or the median 
(interquartile ranges) based on the results of the Shapiro-Wilk normality test. 
Student's t-test or the Mann-Whitney U test was used according to their 
normality. For comparison of more than two groups, one- or two-way 
ANOVA using Tukey’s test was performed. Statistical analyses were 
performed using SPSS version 22 (IBM software, USA) and GraphPad 
Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Statistical 
significance was determined at P < 0.05.
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Results
In the progressive kidney injury model, fibrosis was 
attenuated in periostin null mice.
To determine the role of periostin in the progression of AKI to kidney 
fibrosis (designated as “progressive kidney injury”), UIRI was induced in 
WT mice and Postn null mice and the animals were observed for 6 weeks.
After 6 weeks of disease induction, the left kidneys of WT mice were 
shrunk and smaller in weight than those in the sham group. However, the 
left kidneys in Postn null mice were significantly less atrophied and larger 
in weight compared to those of WT mice (WT UIRI vs. Postn null UIRI, 
0.30 ± 0.05 vs. 0.50 ± 0.17; P = 0.004) (Figure 1A).
Consistent with these findings, WT mice exhibited more prominent 
histological changes, including tubular atrophic changes, interstitial fibrosis, 
and collagen fiber deposition, compared with those of control mice. In 
contrast, the pathologic changes of Postn null mice kidneys were less 
extensive than those of the WT mice (Figure 1B). The expressions of 
collagen 1A1 (WT UIRI vs. Postn null UIRI, 24.96 ± 1.46 vs. 17.10 ± 
3.09; P = 0.012) and S100A4 were also significantly alleviated in Postn 
null mice compared with those in WT mice.
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Figure 1. In progressive kidney injury model, fibrosis was attenuated in periostin 
null mice. (A) Gross features and kidney weights after 6 weeks of disease 
induction. At 6 weeks after disease induction, the left kidneys of Postn null mice 
were significantly less atrophied and weighted more compared to those of WT mice 
(n = 8/group; **P < 0.01).
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(B) Masson’s trichrome stain, sirius red stain, and immunohistochemistry of fibrosis 
markers. Postn null mice showed less extensive pathologic changes and expressions 
of collagen 1A1 and S100A4 compared with those of the WT mice (n = 8/group; 
*P < 0.05, **P < 0.01; magnification: ×40). Data are shown as mean ± standard 
deviation and Student's t-test was used. These results represent one of three 
independent experiments.
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Similar to the histological and clinical changes, the mRNA expressions of 
several fibrosis markers, such as α-SMA, fibronectin, collagen 1A1, TGF-β1, 
and periostin (WT sham vs. WT UIRI 1.18 ± 0.60 vs. 58.15 ± 97.64; P < 
0.001), were significantly elevated in WT mice compared to those in control 
mice and were prominently attenuated in Postn null mice (Figure 2A).
Figure 2. Intrarenal expressions of fibrosis markers in the progressive kidney injury 
model. (A) The mRNA levels of fibrosis markers. In real-time PCR, the expressions 
of various fibrosis markers, including α-SMA, fibronectin, collagen 1A1, TGF-β1, 
and periostin, were significantly elevated in WT mice compared to those in control 
mice and were significantly attenuated in Postn null mice (n = 10/group; ***P < 
0.001). 
17
In addition, western blot analyses of all tissue protein samples were 
performed and the band densities were analyzed. The results of 
representative samples are shown in Figure 2B. The results also indicated 
that the expressions of α-SMA and FSP-1 were greater in WT mice than 
those in Postn null mice, whereas E-cadherin expression significantly 
increased in Postn null mice compared to that in WT mice.
(B) The protein levels of fibrosis markers. In densitometry analyses of western blot 
results and the results of representative samples, the expressions of α-SMA and 
FSP-1 were substantially elevated in WT mice compared to that in control mice and 
were significantly attenuated in Postn null mice. In contrast, E-cadherin was 
prominently expressed in Postn null mice rather than in WT mice (n = 10/group; 
*P < 0.05). Data are shown as mean ± standard deviation and Student's t-test was 
used. These results represent one of three independent experiments. 
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In the progressive kidney injury model, apoptosis was 
decreased in periostin null mice.
Firstly, to verify the relationship between progressive kidney injury and 
apoptosis, the expression of cleaved caspase-3 was examined in the kidney 
tissues 6 weeks after disease induction (Figure 3A). The highly expressed 
cleaved caspase-3 in WT mice was significantly decreased in Postn null
mice.
Figure 3. In the progressive kidney injury model, apoptosis was decreased in 
periostin null mice. (A) The expression of cleaved caspase-3. The expression of 
cleaved caspase-3 in kidney tissues 6 weeks after disease induction was significantly 
decreased in Postn null mice compared to that in WT mice (n = 8/group; **P < 
0.01; magnification: ×200).
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Next, mRNA and protein levels of apoptosis markers were quantified 
using real-time PCR and western blot analyses (Figure 3B). Caspase-9, 
GSK3β, and p53 (WT sham vs. WT UIRI vs. Postn null UIRI 1.00 ± 0.09 
vs. 2.77 ± 0.92 vs. 1.44 ± 0.67; P < 0.001) substantially increased in WT 
mice along with the development of progressive kidney injury compared to 
those in Postn null mice. In contrast, the expression of Bcl-2 was higher in 
Postn null mice than that in WT mice.
(B) The mRNA and protein levels of apoptosis markers. Caspase-9, GSK3β, and 
p53 were significantly increased in WT compared to those in Postn null mice; 
however, Bcl-2 was higher in Postn null mice than that in WT mice (n = 10/group; 
*P < 0.05, **P < 0.01, ***P < 0.001). Data are shown as mean ± standard 
deviation and Student's t-test was used. These results represent one of three 
independent experiments.
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Inhibition of p38 MAPK ameliorated hypoxia-induced 
fibrosis. 
Further, the role of p38 MAPK inhibition was demonstrated using in vivo
and in vitro models. First, phospho-p38 MAPK expressions in the kidney 
tissue and kidney mRNA were measured. The enhanced tissue expressions of 
phospho-p38 MAPK in WT mice compared to those in control mice were 
substantially decreased in Postn null mice as shown by 
immunohistochemistry assays (Figure 4A) and immunofluorescence staining 
(Figure 4B).
Consistent with these findings, the mRNA level of p38 MAPK was 
significantly elevated in WT mice compared to that in control mice and was 
significantly decreased in Postn null mice (WT sham vs. WT UIRI vs. 
Postn null UIRI 1.14 ± 0.50 vs. 5.16 ± 8.72 vs. 1.79 ± 1.16; P < 0.0001, 
P = 0.006) (Figure 4C).
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Figure 4. Inhibition of p38 MAPK ameliorated hypoxia-induced fibrosis. (A) The 
expression of phospho-p38 MAPK in immunohistochemistry. For in vivo studies, 
intrarenal phospho-p38 MAPK expression enhanced in WT mice was substantially 
ameliorated in Postn null mice (n = 8/group; *P < 0.05; magnification: ×40 (upper 
panel), ×200 (lower panel)).
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(B) The expression of phospho-p38 MAPK in immunofluorescence staining. Tissue
phospho-p38 MAPK expression enhanced in WT mice was ameliorated in Postn null
mice as determined by immunofluorescence staining (n = 8/group; magnification: 
×800).
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(C) The expression of p38 MAPK in real-time PCR. The mRNA level of p38 
MAPK was significantly elevated in WT mice compared to that in control mice and 
was, significantly decreased in Postn null mice (n = 10/group; **P < 0.01, ***P < 
0.001) Data are shown as mean ± standard deviation and Student's t-test was used. 
These results represent one of three independent experiments.
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Second, for in vitro studies, the early expression of phospho-p38 MAPK 
was confirmed through confocal microscopic examination (Figure 5A). The 
HK-2 cells incubated in hypoxic conditions for 24 hours increased 
phospho-p38 MAPK expression, which was similar to the results following 
treatment with rTGF-β1 under normoxic conditions. Furthermore, hypoxia in 
combination with rPeriostin significantly magnified the expression of 
phospho-p38 MAPK, which was also comparable to that following treatment 
with rTGF-β1 under hypoxia.
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Figure 5. For in vitro studies, the effects of p38 MAPK inhibition. (A) The 
expression of phospho-p38 MAPK in HK-2 cells. For in vitro studies, hypoxia 
injury for 24 hours resulted in phospho-p38 MAPK expression, which was 
comparable to that with rTGF-β1 under normoxia. In addition, the expression of 
phospho-p38 MAPK under hypoxia was substantially augmented by the 
administration of rPeriostin, which was comparable to that with rTGF-β1 under 
hypoxia (**P < 0.01, ***P < 0.001; magnification: ×800).
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Finally, to confirm the hypothesis that p38 MAPK inhibition affected 
fibrosis markers, HK-2 cells cultured with rTGF-β1 at normoxic condition 
and with a p38 MAPK inhibitor at hypoxic condition were harvested after 5 
days. Hypoxia injury enhanced the fibronectin, collagen 1A1, α-SMA, 
periostin, and snail expressions comparable to or much greater than those 
following treatment with rTGF-β1 under normoxia; however, these 
expressions were substantially mitigated by the use of the p38 MAPK 
inhibitor (dose-dependent). In contrast, decreased E-cadherin expression under 
hypoxia injury was significantly augmented by p38 MAPK inhibition (Figure 
5B).
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(B) Western blot analysis. HK-2 cells were cultured with rTGF-β1 at normoxic 
conditions and with a p38 MAPK inhibitor in hypoxic conditions. After 5 days, the 
expression of fibronectin, collagen 1A1, α-SMA, periostin, and snail following 
hypoxia injury were observed, which were comparable to or much greater than that 
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with rTGF-β1 treatment under normoxia. However, the addition of the p38 MAPK 
inhibitor markedly alleviated these changes. Decreased expression of E-cadherin 
under hypoxia was increased by p38 MAPK inhibition. (*P < 0.05, **P < 0.01, 
***P < 0.001). Data are shown as mean ± standard deviation and Student's t-test 
was used. These results represent one of three independent experiments. After 
densitometry analyses of the results of western blot analyses for all cellular protein 
samples, the results of representative samples are shown in the figure.
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Discussion 
In this study, an experimental model of the progression from AKI to 
CKD was established and the association between periostin and this model 
was investigated. The protective effects of periostin suppression and a 
correlation with the p38 MAPK pathway were also identified.
The unilateral IRI in vivo model established in this study represented the 
progression to CKD after 6 weeks following AKI induced by ischemia and 
hypoxic injury, which has become an important issue recently [28]. This 
experimental model is relevant due to the clinical importance of progression 
from AKI to CKD. 
In a previous study, periostin mRNA expression in tissues was expressed 
in inverse proportion to renal function of the patients with various kidney 
diseases accompanied with tubulo-interstitial fibrosis or glomerular injury
[12]. In addition, the mRNA level of periostin was significantly associated 
with proteinuria, serum Cr level, and renal blood flow in a hypertensive 
nephropathy rat model [14]. Bancha et al. also demonstrated the expression 
of periostin in 5/6 nephrectomy, streptozotocin-induced diabetic nephropathy, 
and unilateral ureteral obstruction in vivo models [29]. For the in vitro
model using human collecting duct cells, periostin was also highly expressed 
following rTGF-β1 administration in a dose-dependent manner, and periostin 
increased the expression of collagen 1A1 [30]. 
Most recently, it was found that urine periostin levels were correlated 
with renal pathologies and longer-term renal outcomes in patients with IgA 
nephropathy [31]. Similarly, the finding that periostin was closely related to 
renal function and tissue fibrosis, has been confirmed in the human samples 
and in the newly established fibrosis model (progressive kidney injury 
model). 
Furthermore, this study examined the protective effects of periostin 
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suppression through experiments using the Postn null mice. The effects of 
periostin suppression have been reported by several studies. Cultured mouse 
distal collecting tubular cells transfected with periostin cDNA exhibited 
increased periostin expression with fibrosis induction; however, those treated 
with periostin siRNA showed attenuation of fibrosis [29]. Most recently, in 
a unilateral ureteral obstruction in vivo model using Postn null mice [30], 
fibrosis was significantly alleviated compared to that in WT mice.
In this study, the unilateral IRI model using Postn null mice showed that 
the changes in gross appearance, fibrosis, and apoptosis were less severe 
compared with those of the WT mice. Through these findings, the protective 
effect of periostin suppression on the progression of AKI to CKD was 
verified. These results were also consistent with those of Oka et al., who 
reported that Postn null mice exhibited less severe infiltration of fibroblasts 
and scarring of left ventricle following myocardial infarction, and better 
long-term cardiac function than those in WT mice [32].
Meanwhile, the association between the p38 MAPK pathway and periostin 
in the progression of AKI to CKD was investigated. p38 MAPK, a 
serine/threonine kinase, regulates several cellular activities including gene 
expression, mitosis, differentiation, migration, survival, and apoptosis in 
response to extracellular stimulation. It is activated by pro-inflammatory 
cytokines, pathogens, growth factors, and environmental factors such as 
hypoxia, ischemia, and reactive oxygen species; therefore, it plays an 
important role in initiation and progression of inflammatory reactions. The 
p38 MAPK cascade is primarily found in macrophages, endothelial cells, 
myocardial cells, and renal cells [33-37]. Previous studies have shown the 
effect of activation or suppression of p38 MAPK on various diseases.
Suppression of p38 MAPK decreased inflammation and necrosis, and 
improved microvascular function and coronary blood flow, which resulted in 
an improvement in interstitial and perivascular fibrosis [38, 39]. In an 
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ischemia-reperfusion injury model, proteinuria, acute tubular necrosis, and 
finally kidney fibrosis and mortality decreased following administration of a 
p38 MAPK inhibitor [34, 40, 41]. Moreover, several kidney disease models 
[35, 36] demonstrated that p38 MAPK inhibition caused prominent 
alleviation of renal function decline, proteinuria, inflammation, glomerular 
sclerosis, and interstitial fibrosis. 
Consistent with these findings, the present study demonstrated an increase 
in phospho-p38 MAPK after disease induction in both in vivo and in vitro
models, and a dose-dependent decrease in fibrosis markers following addition 
of a p38 MAPK inhibitor. These findings indicated a crucial role of p38 
MAPK in fibrosis due to hypoxia and ischemia injury and that the effects 
of periostin were related to the p38 MAPK pathway, given the decreased 
expression of phospho-p38 MAPK in Postn null mice.
Several limitations to this study should be noted. First, the effects of a 
p38 MAPK inhibitor were not examined for in vivo study. However, 
hypoxia-induced fibrosis using the in vitro model clearly demonstrated the 
effects of p38 MAPK inhibition on progressive kidney injury. Second, the 
differences and changes over time were not investigated for the in vivo
model; however, in preliminary experiments, increased expression of periostin 
was found after 2 days of bilateral IRI induction, which was conventional 
AKI in vivo model. Third, the in-depth mechanisms underlying the 
association between periostin and the p38 MAPK pathway in the progression 
of AKI to CKD were not elucidated. Ultimately, further studies regarding 
these mechanisms should be performed. 
Nevertheless, this study first established the correlation between 
periostin/periostin suppression and a progressive kidney injury model through 
changes in fibrosis or apoptosis, and by extension, confirmed the 
dose-dependent effects of p38 MAPK inhibition in in vitro study. In 
conclusion, periostin was related to the progression to kidney fibrosis via the 
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p38 MAPK pathway following acute kidney injury triggered by hypoxic or 
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국문요약
Periostin이 급성신손상 후 




서론: 페리오스틴은 모세포 단백질(matricellular protein) 중 하나로 섬유
화 과정에 중요한 역할을 한다고 알려져 있다. 급성신손상은 만성콩팥병
진행의 중요한 위험 인자이다. 본 연구에서는 급성신손상이 신 섬유화로
진행하는데 있어 페리오스틴이 관여한다는 가설을 세웠다.
방법: 동물실험으로, 7-8 주령의 수컷 표준형(wild-type) 마우스와 페리
오스틴 결핍(periostin null) 마우스를 이용하여 일측성 허혈-재관류 손
상을 유도하였고, 6주 동안 관찰하였다. 생체 외 실험을 위해, 사람 신장
-2 (human kidney-2) 세포를 저산소 세포 배양기(5% O2, 5% CO2, and
90% N2)에 넣어 24시간과 5일 동안 배양하였다. 일부 세포에는 p38 미
토겐 활성화 단백질 키나아제(mitogen-activated protein kinase, MAPK)
억제제를 처리하여 5일간 배양하였다.
결과: 일측성 허혈-재관류 손상을 유도하고 6주 후, 표준형 마우스에 비
하여 periostin null 마우스의 좌측 신장은 덜 위축되었고 세뇨관 위축성
변화와 간질 섬유화도 유의하게 완화되었다. 또한, 표준형 마우스와 비교
하였을 때, periostin null 마우스에서 phosphorylated p38 MAPK의 발
현이 유의하게 감소하였을 뿐 아니라, 다양한 섬유화 및 세포자멸
(apoptosis) 마커들의 mRNA와 단백 발현이 약화되는 것을 확인하였다.
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생체 외 실험에서는, 사람 신장-2 세포에 각각 24시간과 5일 동안 저산
소 자극(5% O2, 5% CO2, and 90% N2)을 주었을 때, phospho-p38
MAPK 및 다양한 섬유화 마커의 발현이 증가함을 확인하였다. 저산소
상태에서 재조합 페리오스틴을 처리하였을 때 phospho-p38 MAPK 발현
이 더 증가하였는데, 이는 재조합 transforming growth factor-β1을 처
리하였을 때의 결과와 비슷한 정도였다. 반면, p38 MAPK를 억제하였을
때는 저산소 유도 섬유화가 개선되는 결과를 보였다.
결론: 결론적으로, 페리오스틴은 저산소증 및 허혈성 자극에 의한 급성
신손상 후 동반되는 신 섬유화 진행에 관여하며 이는 p38 MAPK 경로
와 연관되어 있다. 페리오스틴을 억제하는 것은 신 섬유화 진행에 예방
효과(protective effect)를 가지는 것으로 생각된다.
----------------------------------------------------------------------------------------------------
주요어: 페리오스틴, 급성신손상, 신 섬유화, 저산소증, periostin null
mice, 일측성 허혈-재관류 손상, p38 mitogen-activated protein kinase
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